Export 10 results:
Author Title [ Type(Asc)] Year
Filters: Author is Cutler, Corey  [Clear All Filters]
Presentation
M. E. Horwitz, tiff, P., Rezvani, A. R., Hwang, W. Ying Khee, Karras, N., Valcarcel, D., Koh, L. Piu, yasser, K., Keating, A. K., Segalovich, I., Sanz, G., Cutler, C., Brunstein, C. G., Hanna, R., McGuirk, J. P., Lindemans, C. A., Maziarz, R. T., Schiller, G. J., Hammerschlak, N., Frankfurt, O., Blackwell, B., and Galamidi, E., “Improved Clinical Outcomes with Omidubicel versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized, Multicenter Study”. 2021.
Journal Article
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. - H., Carter, S. L., Horowitz, M. M., and Antin, J. H., “Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.”, Blood, vol. 124, no. 8, pp. 1372-7, 2014.
C. Cutler, Stevenson, K., Kim, H. T., Richardson, P., Ho, V. T., Linden, E., Revta, C., Ebert, R., Warren, D., Choi, S., Koreth, J., Armand, P., Alyea, E., Carter, S., Horowitz, M., Antin, J. H., and Soiffer, R., “Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.”, Blood, vol. 112, no. 12, pp. 4425-31, 2008.
M. Abu Zaid, Wu, J., Wu, C., Logan, B. R., Yu, J., Cutler, C., Antin, J. H., Paczesny, S., and Choi, S. Won, “Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.”, Blood, vol. 129, no. 2, pp. 162-170, 2017.
K. Ballen, Mendizabal, A. M., Cutler, C., Politikos, I., Jamieson, K., Shpall, E. J., Dey, B. R., Attar, E., McAfee, S., Delaney, C., McCarthy, P., Ball, E. D., Kamble, R., Avigan, D., Maziarz, R. T., Ho, V. T., Koreth, J., Alyea, E., Soiffer, R., Wingard, J. R., Boussiotis, V., Spitzer, T. R., and Antin, J. H., “Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.”, Biol Blood Marrow Transplant, vol. 18, no. 12, pp. 1851-8, 2012.
M. E. Horwitz, Stiff, P. J., Cutler, C., Brunstein, C., Hanna, R., Maziarz, R. T., Rezvani, A. R., Karris, N. A., McGuirk, J., Valcarcel, D., Schiller, G. J., Lindemans, C. A., Hwang, W. Y. K., Koh, L. Piu, Keating, A., Khaled, Y., Hamerschlak, N., Frankfurt, O., Peled, T., Segalovich, I., Blackwell, B., Wease, S., Freedman, L. S., Galamidi-Cohen, E., and Sanz, G., “Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.”, Blood, vol. 138, no. 16, pp. 1429-1440, 2021.
J. Pidala, Martens, M., Anasetti, C., Carreras, J., Horowitz, M., Lee, S. J., Antin, J., Cutler, C., and Logan, B., “Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.”, JAMA Oncol, 2019.
S. J. Lee, Logan, B., Westervelt, P., Cutler, C., Woolfrey, A., Khan, S. P., Waller, E. K., Maziarz, R. T., Wu, J., Shaw, B. E., Confer, D., Horowitz, M. M., and Anasetti, C., “Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.”, JAMA Oncol, vol. 2, no. 12, pp. 1583-1589, 2016.
V. T. Ho, Cutler, C., Carter, S., Martin, P., Adams, R., Horowitz, M., Ferrara, J., Soiffer, R., and Giralt, S., “Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.”, Biol Blood Marrow Transplant, vol. 11, no. 8, pp. 571-5, 2005.
R. Nakamura, Saber, W., Martens, M. J., Ramirez, A., Scott, B., Oran, B., Leifer, E., Tamari, R., Mishra, A., Maziarz, R. T., McGuirk, J., Westervelt, P., Vasu, S., Patnaik, M., Kamble, R., Forman, S. J., Sekeres, M. A., Appelbaum, F., Mendizabal, A., Logan, B., Horowitz, M., and Cutler, C., “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.